115 related articles for article (PubMed ID: 38054226)
1. Prognostic model for assessing the human glioma cell malignancy grade based on MDM2, MELK, SOX2, CDK4, DR5 and OCT4 gene expression.
Tyagunova EE; Drozd SF; Kalennik OV; Samoylenkova NS; Savchenko EA; Danilov GV; Pavlova GV
Zh Vopr Neirokhir Im N N Burdenko; 2023; 87(6):43-51. PubMed ID: 38054226
[TBL] [Abstract][Full Text] [Related]
2. MDM2 and CDK4 immunohistochemistry is a valuable tool in the differential diagnosis of low-grade osteosarcomas and other primary fibro-osseous lesions of the bone.
Dujardin F; Binh MB; Bouvier C; Gomez-Brouchet A; Larousserie F; Muret Ad; Louis-Brennetot C; Aurias A; Coindre JM; Guillou L; Pedeutour F; Duval H; Collin C; de Pinieux G
Mod Pathol; 2011 May; 24(5):624-37. PubMed ID: 21336260
[TBL] [Abstract][Full Text] [Related]
3. Real-time polymerase chain reaction analysis of MDM2 and CDK4 expression using total RNA from core-needle biopsies is useful for diagnosing adipocytic tumors.
Sasaki T; Ogose A; Kawashima H; Hotta T; Hatano H; Ariizumi T; Umezu H; Ohashi R; Tohyama T; Tanabe N; Endo N
BMC Cancer; 2014 Jun; 14():468. PubMed ID: 24965044
[TBL] [Abstract][Full Text] [Related]
4. Expression profile of embryonic stem cell-associated genes Oct4, Sox2 and Nanog in human gliomas.
Guo Y; Liu S; Wang P; Zhao S; Wang F; Bing L; Zhang Y; Ling EA; Gao J; Hao A
Histopathology; 2011 Oct; 59(4):763-75. PubMed ID: 22014056
[TBL] [Abstract][Full Text] [Related]
5. [LincRNA-ROR functions as a ceRNA to regulate Oct4, Sox2, and Nanog expression by sponging miR-145 and its effect on biologic characteristics of colonic cancer stem cells].
Yan ZY; Sun XC
Zhonghua Bing Li Xue Za Zhi; 2018 Apr; 47(4):284-290. PubMed ID: 29690669
[No Abstract] [Full Text] [Related]
6. Clinical and biological significance of CDK4 amplification in well-differentiated and dedifferentiated liposarcomas.
Italiano A; Bianchini L; Gjernes E; Keslair F; Ranchere-Vince D; Dumollard JM; Haudebourg J; Leroux A; Mainguené C; Terrier P; Chibon F; Coindre JM; Pedeutour F
Clin Cancer Res; 2009 Sep; 15(18):5696-703. PubMed ID: 19737942
[TBL] [Abstract][Full Text] [Related]
7. Amplification of FRS2 and activation of FGFR/FRS2 signaling pathway in high-grade liposarcoma.
Zhang K; Chu K; Wu X; Gao H; Wang J; Yuan YC; Loera S; Ho K; Wang Y; Chow W; Un F; Chu P; Yen Y
Cancer Res; 2013 Feb; 73(4):1298-307. PubMed ID: 23393200
[TBL] [Abstract][Full Text] [Related]
8. MELK inhibition targets cancer stem cells through downregulation of SOX2 expression in head and neck cancer cells.
Ren L; Deng B; Saloura V; Park JH; Nakamura Y
Oncol Rep; 2019 Apr; 41(4):2540-2548. PubMed ID: 30720113
[TBL] [Abstract][Full Text] [Related]
9. Tumor-specific activation of the C-JUN/MELK pathway regulates glioma stem cell growth in a p53-dependent manner.
Gu C; Banasavadi-Siddegowda YK; Joshi K; Nakamura Y; Kurt H; Gupta S; Nakano I
Stem Cells; 2013 May; 31(5):870-81. PubMed ID: 23339114
[TBL] [Abstract][Full Text] [Related]
10. Detection of MDM2-CDK4 amplification by fluorescence in situ hybridization in 200 paraffin-embedded tumor samples: utility in diagnosing adipocytic lesions and comparison with immunohistochemistry and real-time PCR.
Sirvent N; Coindre JM; Maire G; Hostein I; Keslair F; Guillou L; Ranchere-Vince D; Terrier P; Pedeutour F
Am J Surg Pathol; 2007 Oct; 31(10):1476-89. PubMed ID: 17895748
[TBL] [Abstract][Full Text] [Related]
11. MDM2 and CDK4 immunohistochemical coexpression in high-grade osteosarcoma: correlation with a dedifferentiated subtype.
Yoshida A; Ushiku T; Motoi T; Beppu Y; Fukayama M; Tsuda H; Shibata T
Am J Surg Pathol; 2012 Mar; 36(3):423-31. PubMed ID: 22301501
[TBL] [Abstract][Full Text] [Related]
12. SOX2-RNAi attenuates S-phase entry and induces RhoA-dependent switch to protease-independent amoeboid migration in human glioma cells.
Oppel F; Müller N; Schackert G; Hendruschk S; Martin D; Geiger KD; Temme A
Mol Cancer; 2011 Nov; 10():137. PubMed ID: 22070920
[TBL] [Abstract][Full Text] [Related]
13. MDM2 Degrades Deacetylated Nucleolin Through Ubiquitination to Promote Glioma Stem-Like Cell Enrichment for Chemotherapeutic Resistance.
Ko CY; Lin CH; Chuang JY; Chang WC; Hsu TI
Mol Neurobiol; 2018 Apr; 55(4):3211-3223. PubMed ID: 28478507
[TBL] [Abstract][Full Text] [Related]
14. Central chondrosarcoma progression is associated with pRb pathway alterations: CDK4 down-regulation and p16 overexpression inhibit cell growth in vitro.
Schrage YM; Lam S; Jochemsen AG; Cleton-Jansen AM; Taminiau AH; Hogendoorn PC; Bovée JV
J Cell Mol Med; 2009 Sep; 13(9A):2843-52. PubMed ID: 18624751
[TBL] [Abstract][Full Text] [Related]
15. Characterization of the 12q15 MDM2 and 12q13-14 CDK4 amplicons and clinical correlations in osteosarcoma.
Mejia-Guerrero S; Quejada M; Gokgoz N; Gill M; Parkes RK; Wunder JS; Andrulis IL
Genes Chromosomes Cancer; 2010 Jun; 49(6):518-25. PubMed ID: 20196171
[TBL] [Abstract][Full Text] [Related]
16. Co-expression of MDM2 and CDK4 in transformed human mesenchymal stem cells causes high-grade sarcoma with a dedifferentiated liposarcoma-like morphology.
Kim YJ; Kim M; Park HK; Yu DB; Jung K; Song K; Choi YL
Lab Invest; 2019 Sep; 99(9):1309-1320. PubMed ID: 31160689
[TBL] [Abstract][Full Text] [Related]
17. Differential patterns of NOTCH1-4 receptor expression are markers of glioma cell differentiation.
Dell'albani P; Rodolico M; Pellitteri R; Tricarichi E; Torrisi SA; D'Antoni S; Zappia M; Albanese V; Caltabiano R; Platania N; Aronica E; Catania MV
Neuro Oncol; 2014 Jan; 16(2):204-16. PubMed ID: 24305720
[TBL] [Abstract][Full Text] [Related]
18. Glioma SOX2 expression decreased after adjuvant therapy.
Yu W; Ren X; Hu C; Tan Y; Shui Y; Chen Z; Zhang L; Peng J; Wei Q
BMC Cancer; 2019 Nov; 19(1):1087. PubMed ID: 31718604
[TBL] [Abstract][Full Text] [Related]
19. Suppression of long non-coding RNA PCAT19 inhibits glioma cell proliferation and invasion, and increases cell apoptosis through regulation of MELK targeted by miR-142-5p.
Xie YH; Hu J
Genes Genomics; 2020 Nov; 42(11):1299-1310. PubMed ID: 32980991
[TBL] [Abstract][Full Text] [Related]
20. MiR-181b sensitizes glioma cells to teniposide by targeting MDM2.
Sun YC; Wang J; Guo CC; Sai K; Wang J; Chen FR; Yang QY; Chen YS; Wang J; To TS; Zhang ZP; Mu YG; Chen ZP
BMC Cancer; 2014 Aug; 14():611. PubMed ID: 25151861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
